What is Daridorexant's Approved Use?
Daridorexant is a medication approved for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance [1].
How is Daridorexant Synthesized?
The synthesis of daridorexant involves several chemical steps. One described route begins with a chiral starting material, (S)-1-(2-fluorophenyl)ethanamine, which is reacted with tert-butyl (2-chloro-5-methoxypyridin-3-yl)carbamate. This is followed by a cyclization step using sodium hydride, yielding an intermediate. Subsequent reactions include acetylation, deprotection, and finally, coupling with 2-(5-methoxy-2-oxo-1,2-dihydropyridin-3-yl)acetic acid to form daridorexant. This process highlights the use of specific reagents and conditions to construct the molecule [2].
When Does Daridorexant's Main Patent Expire?
Information on the precise expiration date of the main patent for daridorexant is not publicly available in the provided text. However, patent lifecycles and exclusivities are crucial for pharmaceutical products. For detailed patent status and expiration timelines, resources such as DrugPatentWatch.com can be consulted [3].
What are Potential Challenges to Daridorexant's Patents?
Pharmaceutical patents, including those for medications like daridorexant, can be subject to legal challenges. These challenges often aim to invalidate existing patents or argue that a new generic product does not infringe upon them. Such litigation can impact the market exclusivity period for a drug [3].
What Other Drugs are Similar to Daridorexant?
Daridorexant belongs to the class of orexin receptor antagonists, which also includes drugs like suvorexant and lemborexant. These medications work by blocking the action of orexin, a neurotransmitter that promotes wakefulness [1].